Logo image of VRNA

VERONA PHARMA PLC - ADR (VRNA) Stock Fundamental Analysis

NASDAQ:VRNA - Nasdaq - US9250501064 - ADR - Currency: USD

72.52  -0.21 (-0.29%)

Fundamental Rating

3

VRNA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. VRNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. VRNA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VRNA has reported negative net income.
In the past year VRNA has reported a negative cash flow from operations.
In the past 5 years VRNA always reported negative net income.
VRNA had a negative operating cash flow in each of the past 5 years.
VRNA Yearly Net Income VS EBIT VS OCF VS FCFVRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

VRNA has a Return On Assets (-36.57%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -84.78%, VRNA is in line with its industry, outperforming 44.44% of the companies in the same industry.
Industry RankSector Rank
ROA -36.57%
ROE -84.78%
ROIC N/A
ROA(3y)-26.9%
ROA(5y)-28.47%
ROE(3y)-45.46%
ROE(5y)-41.83%
ROIC(3y)N/A
ROIC(5y)N/A
VRNA Yearly ROA, ROE, ROICVRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

With an excellent Gross Margin value of 93.89%, VRNA belongs to the best of the industry, outperforming 96.46% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for VRNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRNA Yearly Profit, Operating, Gross MarginsVRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

5

2. Health

2.1 Basic Checks

VRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
VRNA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, VRNA has more shares outstanding
The debt/assets ratio for VRNA is higher compared to a year ago.
VRNA Yearly Shares OutstandingVRNA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VRNA Yearly Total Debt VS Total AssetsVRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 12.15 indicates that VRNA is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 12.15, VRNA belongs to the best of the industry, outperforming 89.90% of the companies in the same industry.
VRNA has a Debt/Equity ratio of 0.59. This is a neutral value indicating VRNA is somewhat dependend on debt financing.
VRNA has a Debt to Equity ratio of 0.59. This is in the lower half of the industry: VRNA underperforms 62.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.59
Debt/FCF N/A
Altman-Z 12.15
ROIC/WACCN/A
WACC9.29%
VRNA Yearly LT Debt VS Equity VS FCFVRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 10.63 indicates that VRNA has no problem at all paying its short term obligations.
The Current ratio of VRNA (10.63) is better than 84.34% of its industry peers.
A Quick Ratio of 10.48 indicates that VRNA has no problem at all paying its short term obligations.
VRNA has a Quick ratio of 10.48. This is amongst the best in the industry. VRNA outperforms 83.84% of its industry peers.
Industry RankSector Rank
Current Ratio 10.63
Quick Ratio 10.48
VRNA Yearly Current Assets VS Current LiabilitesVRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for VRNA have decreased strongly by -217.65% in the last year.
The Revenue has been growing slightly by 1.86% on average over the past years.
EPS 1Y (TTM)-217.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-122.22%
Revenue 1Y (TTM)N/A
Revenue growth 3Y1.86%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 19.15% on average over the next years. This is quite good.
Based on estimates for the next years, VRNA will show a very strong growth in Revenue. The Revenue will grow by 104.61% on average per year.
EPS Next Y113.51%
EPS Next 2Y66.62%
EPS Next 3Y45.86%
EPS Next 5Y19.15%
Revenue Next Year730.42%
Revenue Next 2Y300.73%
Revenue Next 3Y179.7%
Revenue Next 5Y104.61%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VRNA Yearly Revenue VS EstimatesVRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
VRNA Yearly EPS VS EstimatesVRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

VRNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 248.59, which means the current valuation is very expensive for VRNA.
Based on the Price/Forward Earnings ratio, VRNA is valued a bit cheaper than the industry average as 74.24% of the companies are valued more expensively.
VRNA is valuated expensively when we compare the Price/Forward Earnings ratio to 20.81, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 248.59
VRNA Price Earnings VS Forward Price EarningsVRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150 200

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRNA Per share dataVRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates VRNA does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as VRNA's earnings are expected to grow with 45.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y66.62%
EPS Next 3Y45.86%

More info and screens

0

5. Dividend

5.1 Amount

VRNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERONA PHARMA PLC - ADR

NASDAQ:VRNA (5/5/2025, 3:32:36 PM)

72.52

-0.21 (-0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-29 2025-04-29
Earnings (Next)08-06 2025-08-06
Inst Owners71.35%
Inst Owner Change1.95%
Ins Owners5.81%
Ins Owner Change-3.9%
Market Cap6.17B
Analysts84.71
Price Target81.94 (12.99%)
Short Float %17.2%
Short Ratio5.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.94%
Min EPS beat(2)-34.07%
Max EPS beat(2)-9.8%
EPS beat(4)0
Avg EPS beat(4)-81.91%
Min EPS beat(4)-192.46%
Max EPS beat(4)-9.8%
EPS beat(8)3
Avg EPS beat(8)-26.15%
EPS beat(12)5
Avg EPS beat(12)-22.66%
EPS beat(16)9
Avg EPS beat(16)-4.16%
Revenue beat(2)2
Avg Revenue beat(2)91.2%
Min Revenue beat(2)8.73%
Max Revenue beat(2)173.67%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)25.09%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.67%
EPS NY rev (1m)5.15%
EPS NY rev (3m)165%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)20.99%
Revenue NY rev (1m)0%
Revenue NY rev (3m)41.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 248.59
P/S 145.83
P/FCF N/A
P/OCF N/A
P/B 30.14
P/tB 30.22
EV/EBITDA N/A
EPS(TTM)-2.16
EYN/A
EPS(NY)0.29
Fwd EY0.4%
FCF(TTM)-1.44
FCFYN/A
OCF(TTM)-1.44
OCFYN/A
SpS0.5
BVpS2.41
TBVpS2.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.57%
ROE -84.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.89%
FCFM N/A
ROA(3y)-26.9%
ROA(5y)-28.47%
ROE(3y)-45.46%
ROE(5y)-41.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.59
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 54.82%
Cap/Sales 1.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.63
Quick Ratio 10.48
Altman-Z 12.15
F-Score2
WACC9.29%
ROIC/WACCN/A
Cap/Depr(3y)19.84%
Cap/Depr(5y)14.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-217.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-122.22%
EPS Next Y113.51%
EPS Next 2Y66.62%
EPS Next 3Y45.86%
EPS Next 5Y19.15%
Revenue 1Y (TTM)N/A
Revenue growth 3Y1.86%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year730.42%
Revenue Next 2Y300.73%
Revenue Next 3Y179.7%
Revenue Next 5Y104.61%
EBIT growth 1Y-128.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year166.58%
EBIT Next 3Y91.37%
EBIT Next 5YN/A
FCF growth 1Y-144.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-143.33%
OCF growth 3YN/A
OCF growth 5YN/A